Mediterrania portfolio company Laprophan acquires Rivopharm
The Moroccan pharmaceutical group has acquired a controlling stake in Switzerland-based Rivopharm.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
Mediterrania Capital Partners, a private equity firm focused on growth investments across Africa, has announced that its portfolio company, Laprophan Group, has acquired a controlling stake in Rivopharm. Based in Switzerland, Rivopharm is a pharmaceutical company specialising in speciality medicines, dossier development, complex formulations, and value-added pharmaceutical solutions.
Founded more than 75 years ago, Laprophan is a Morocco-based pharmaceutical group. Since Mediterrania’s investment, the company has pursued an ambitious growth strategy focused on expanding its product portfolio, strengthening its industrial capabilities, and accelerating international expansion.
Through Rivopharm’s Swiss manufacturing and development platform, as well as its subsidiaries in the United Kingdom, Germany and Lithuania, Laprophan gains direct access to key European markets and complementary pharmaceutical capabilities.
Hatim Ben Ahmed, managing partner at Mediterrania Capital Partners, said: “This acquisition is a defining step in that journey. Rivopharm brings highly complementary capabilities, a strong European platform and significant opportunities for value creation. Together, Laprophan and Rivopharm are exceptionally well positioned to build a diversified international pharmaceutical group with a meaningful presence across Europe, Africa and the Middle East. We are proud to support Laprophan’s management team as they continue to execute on their long-term growth strategy.”
Want to know who is raising, investing, and exiting in Africa? Get Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Access the latest Dealmaker’s Log here